{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:24:53Z","timestamp":1789604693594,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>One-third of US adults are bothered by excessive sweating, approximately 5% are diagnosed with hyperhidrosis. A topical patch using targeted alkali thermolysis (TAT) was developed for treatment of this condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>This study was intended to assess the efficacy and safety of the TAT-Patch for axillary sweat reduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>A randomized, multicenter, double-blind, sham-controlled, pivotal trial enrolled 120 subjects to a bilateral axillary treatment with a TAT patch (63 subjects) or sham patch (57 subjects).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The primary end point was achieved; 64% of TAT-treated versus 44% of sham-treated subjects (<jats:italic toggle=\"yes\">p<\/jats:italic> = .0332) improved from Hyperhidrosis Disease Severity Scale (HDSS) 3\/4 to HDDS 1\/2 at 4 weeks. Targeted alkali thermolysis treatment also showed a statistically significant improvement over sham treatment for all secondary end points, including gravimetric sweat production and subject-reported quality-of-life (QoL) assessments. The duration of effect is approximately 3 months, determined by the time to return to baseline HDSS. Mild-to-moderate treatment-site adverse events (AEs) were reported in 22% of TAT patch subjects. No serious or severe AEs were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>HDSS, GSP, and QoL findings confirm clinically meaningful sweat reduction and a significant improvement in quality of life following a single TAT patch treatment. This device has potential to offer a new, noninvasive treatment option that is well tolerated with minimal downtime.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004472","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:00:20Z","timestamp":1730386820000},"page":"1182-1187","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["A Pivotal Study on the Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating"],"prefix":"10.1097","volume":"50","author":[{"given":"Stacy","family":"Smith","sequence":"first","affiliation":[{"name":"California Dermatology and Clinical Research Institute, Encinitas, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee Anna","family":"Glaser","sequence":"additional","affiliation":[{"name":"Glaser Dermatology & Aesthetics LLC, St. Louis, Missouri;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawerence J.","family":"Green","sequence":"additional","affiliation":[{"name":"Dept of Dermatology, George Washington University School of Medicine, Washington, District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal S.","family":"Kaminer","sequence":"additional","affiliation":[{"name":"SkinCare Physicians, Chestnut Hill, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Tims","sequence":"additional","affiliation":[{"name":"Candesant Biomedical, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"R2-20250731","first-page":"1","article-title":"IHHS Sweat Survey reveals many are suffering in silence","year":"2008","journal-title":"Sweat Solutions"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250731","first-page":"392","article-title":"Understanding patient experience with hyperhidrosis: a national survey of 1,985 patients","volume":"17","author":"Glaser","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/DSS.0000000000003598","article-title":"A pilot study of the safety and effectiveness of a novel device in subjects with axillary hyperhidrosis","volume":"48","author":"Kaufman","year":"2022","journal-title":"Dermatol Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00042728-200504000-00006","article-title":"Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life","volume":"31","author":"Solish","year":"2005","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4725.2011.02250.x","article-title":"A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study","volume":"38","author":"Glaser","year":"2012","journal-title":"Dermatol Surg"},{"key":"R11-20250731","first-page":"908","article-title":"A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee","volume":"33","author":"Solish","year":"2007","journal-title":"Dermatol Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","article-title":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","volume":"80","author":"Glaser","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40257-018-0395-0","article-title":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials","volume":"20","author":"Pariser","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/pde.13723","article-title":"Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials","volume":"36","author":"Hebert","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jaad.2020.02.016","article-title":"Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial","volume":"82","author":"Kirsch","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2021.01.030","article-title":"Bromhidrosis treatment modalities: a literature review review","volume":"89","author":"Malik","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:05:59Z","timestamp":1753999559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004472","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}